Jump to content

Thiamylal

From Wikipedia, the free encyclopedia
(Redirected from Surital)
Thiamylal
Clinical data
Other namesThiamylal, Thioseconal, Surital
AHFS/Drugs.comInternational Drug Names
ATCvet code
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic
Elimination half-life14.3 h (cats)
Identifiers
  • 5-(Pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.927 Edit this at Wikidata
Chemical and physical data
FormulaC12H18N2O2S
Molar mass254.35 g·mol−1
3D model (JSmol)
  • O=C1NC(=S)NC(=O)C1(C(C)CCC)C\C=C
  • InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17) checkY
  • Key:XLOMZPUITCYLMJ-UHFFFAOYSA-N checkY
  (verify)

Thiamylal (Surital) is a barbiturate derivative invented in the 1950s. It has sedative, anticonvulsant, and hypnotic effects, and is used as a strong but short acting sedative. Thiamylal is still in current use, primarily for induction in surgical anaesthesia[2] or as an anticonvulsant to counteract side effects from other anaesthetics.[3] It is the thiobarbiturate analogue of secobarbital.

References

[edit]
  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Hsieh MY, Hung GY, Hsieh YL, Chang CY, Hwang B (2005). "Deep sedation with methohexital or thiamylal with midazolam for invasive procedures in children with acute lymphoblastic leukemia". Acta Paediatrica Taiwanica = Taiwan Er Ke Yi Xue Hui Za Zhi. 46 (5): 294–300. PMID 16640004.
  3. ^ Tsai CJ, Wang HM, Lu IC, Tai CF, Wang LF, Soo LY, Lu DV (February 2007). "Seizure after local anesthesia for nasopharyngeal angiofibroma". The Kaohsiung Journal of Medical Sciences. 23 (2): 97–100. doi:10.1016/S1607-551X(09)70383-3. PMID 17339174.